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Canine ehrlichiosis and anaplasmosis are important tick-borne diseases with a worldwide distribution. Information
has been continuously collected on these infections in Europe, and publications have increased in recent years.
Prevalence rates are high for Ehrlichia and Anaplasma spp. infections in dogs from different European countries. The
goal of this article was to provide a practical guideline for veterinary practitioners on the diagnosis, treatment, and
prevention of ehrlichiosis and anaplasmosis in dogs from Europe. This guideline is intended to answer the most
common questions on these diseases from a practical point of view.
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consensusIntroduction
Canine ehrlichiosis and anaplasmosis are important
tick-borne diseases with a worldwide distribution.
Ehrlichia canis was first identified in 1935 in Algeria;
dogs infested with ticks showed fever and anemia [1].
Later, during the Vietnam War, many military working
dogs brought to Vietnam by the US army exhibited a
severe disease called Tropical Canine Pancytopenia [2].
Later, it was renamed canine monocytic ehrlichiosis
(CME).
In 1978, an ehrlichial infection that affected platelets
was first identified in the US. It was caused by Ana-
plasma platys (initially identified as Ehrlichia platys),
and it caused a clinical syndrome known as canine
infectious cyclic thrombocytopenia [3]. In 1982, a nat-
ural infection of granulocytic anaplasmosis, caused by
Ehrlichia phagocytophila, was first identified in dogs in
California. Currently, this species is called Anaplasma
phagocytophilum [4].
Over the 1980’s and 90’s, several species closely re-
lated to E. canis were found in infected dogs. Improve-
ments in molecular techniques indicated that they were* Correspondence: angelehr@vet.ucm.es
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unless otherwise stated.phylogenetically distant from E. canis, and therefore,
they were reclassified under the genera Anaplasma or
Neorickettsia [5].
In 2002, a large amount of information on ehrlichial
infections was gathered by the American College of
Veterinary Internal Medicine (ACVIM) Infectious
Disease Study Group. That group published a Consensus
Statement on diseases caused by Ehrlichia spp. in small
animals [6]. Over the years, and probably as a result of
globalization, urbanization, global warming, increased
trade, and travel, these diseases have spread to new
niches. Recently, diseases caused by Ehrlichia spp have
been reported in many countries that had not previously
detected them. Information has been continuously
collected on these infections, and publications have
increased in recent years. This document was intended
to answer common questions of interest on this group
of infections, with a special focus on the situation in
Europe.Review
What species of Ehrlichia and/or Anaplasma can infect dogs
in Europe?
To date, three species have been clearly identified in dogs
in Europe; E. canis, A. phagocytophilum, and A. platys.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Ehrlichia canis is the only Ehrlichia species that has
been isolated in dogs from Europe [7,8]. To our know-
ledge, other Ehrlichia species (E. chaffeensis, E. ewingii,
E. muris, and E. ruminantium) have not been detected
in dogs from Europe. However, E. muris has been de-
scribed in Ixodes ticks from Russia and Slovakia [9,10].
All European countries bordering the Mediterranean
Sea are endemic for E. canis. Some surveys have indi-
cated that the infectious agent is spreading to countries
north of the Mediterranean (i.e., Switzerland, Germany)
[11-13]. Table 1 shows the prevalence of E. canis infec-
tions in dogs from Europe.Table 1 Prevalence of E. canis infections in dogs of different E
Country Number of dogs (n) Prevale
Albania 30 50.0/17
Finland 340 0.3
France 919 0.3
Germany 106a 0.9
997a 3.1/0
4681a 10.1
Hungary 1305 0.2
Italy 249b 46.0
135 44.0/6.0
51 0
131b 22.9
601 6.4
1000 46.7
423 20.0
Portugal 557 4.1
55 22.0
104 50.0
Romania 1146 2.1
Russia 442c 82d 0 2.4
Spain 1100 5.0
131 5.3
153 4.0e
479 3.1
466 16.7 4.5
200 6.5
308 19.2
Switzerland 996a 2.2
Turkey 284 20.7
aTravelled/imported dogs.
bKenelled dogs.
cDogs with external antiparasitary treatment.
dDogs without external antiparasitary treatment.
eUsing primers for Ehrlichia/Anaplasma.Anaplasma phagocytophilum
Infections of A. phagocytophilum have been described
mainly in northern and central Europe. Epidemiological
studies performed in Europe (Table 2) that evaluated
the seroprevalence (rarely a DNA-based analysis) showed
that 3 to 57% of dogs carried A. phagocytophilum. How-
ever, the different studies investigated different dog popu-
lations (i.e., healthy and sick), and they used different tests
(i.e., immunofluorescent antibody test [IFAT] or enzyme-
linked immunosorbent assay [ELISA]). In addition, sero-
logical cross-reactivity with other Anaplasma spp. (e.g.,
A. platys) can potentially cause an overestimation of the
true seroprevalence.uropean countries
nce (%) Test methods Reference
.0 IFAT/Blood smear [14]
4DX ELISA [15]
4DX ELISA [16]
IFAT [17]
IFAT/PCR [18]
IFAT [19]
4DX ELISA [20]
IFAT [21]
IFAT/PCR [22]
PCR [23]
IFAT [24]
PCR [25]
IFAT [26]
IFAT [27]
4Dx ELISA [28]
PCR [29]
IFAT [30]
4DX ELISA [31]
4DX ELISA [32]
4DX ELISA [33]
4DX ELISA [34]
PCR [35]
IFAT [36]
IFAT 3DX ELISA [37]
IFAT [38]
IFAT [39]
IFAT [13]
IFAT [40]
Table 2 Prevalence of infections with A. phagocytophilum in dogs of different European countries
Country Number of dogs (n) Prevalence (%) Test methods Reference
Austria 1470 56.5 IFAT [41]
Albania 30 40.0/0 IFAT/Blood smear [14]
Finland 340 5.3 4Dx ELISAa [15]
France 919 2.7 4Dx ELISAa [16]
Germany 1124 50.1 IFAT [42]
111 43.2 / 6.3 IFAT/PCR [43]
245 19.2 IFAT [44]
5881 21.5 4Dx ELISAa [45]
522 43.0 / 5.7 IFAT/PCR [46]
448 19.4 4Dx ELISAa [47]
Hungary 1305 7.9 4Dx ELISAa [20]
Italy 344 0 PCR [48]
460 0 PCR [25]
5634 33.0 IFAT [49]
1232 8.8 IFAT [50]
249 38.0 IFAT [21]
215 15.0 / 0.02 IFAT/PCR [51]
Latvia 470 11.4 4Dx ELISAa [52]
Poland 192 1.0 PCR [53]
Portugal 55 55.0/0 IFAT/PCR [54]
Romania 1146 5.5 4DX ELISAa [31]
Russia 442b 82c 1.1 34.1 4Dx ELISAa [32]
Sweden 611 17.7 IFAT [55]
248 20.7 IFAT [56]
Switzerland 996 7.5 IFAT [13]
Spain 649 15.6 IFAT [36]
466 11.5 IFAT [37]
1100 3.1 4Dx ELISAa [33]
United Kingdom 120 0.8 PCR [57]
aThis test cannot differentiate between A. phagocytophilum and A. platys.
bDogs with external antiparasitary treatment.
cDogs without external antiparasitary treatment.
Table 3 Prevalence of infections with A. platys in dogs in
Europe
Country Number of
dogs (n)
Prevalence (%) Test
methods
Reference
Italy 34a 52.9 PCR [65]
34a 70.5 PCR [66]
109a 27.5 PCR [67]
344 4 PCR [48]
100a 23 RLB-PCR [68]
Portugal 55b 9 IFAT/PCR [54]
aKenelled dogs.
bDogs with suspected tick-borne diseases.
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Anaplasma platys has been diagnosed in dogs, particu-
larly from countries in the Mediterranean basin, includ-
ing Italy [48], Spain [58], Portugal [59], France [60],
Turkey [61], Greece [62], Croatia [63], and Romania
[64]. Information is limited regarding the prevalence of
A. platys infections in dogs from Europe, based on a mo-
lecular analysis (Table 3).
What are the vectors and geographic distributions of
vectors for these infections in dogs in Europe?
Ehrlichia canis
The main, and probably the only, vector for E. canis in
Europe is the tick Rhipicephalus sanguineus sensu lato,
known as the brown dog-tick. This tick was shown
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[69,70]. A recent study has shown that transmission of
E. canis by R. sanguineus ticks starts within 3 h after tick
attachment to the dog [71]. The tick vector is currently
considered a complex of species [72]. The details of this
vector’s morphology and molecular biology have been
published, and it has been identified in wide areas of the
world. However, it is difficult to ascertain which “species”
comprise the actual vector, because the description of
the original specimen type has been lost [72].
Rhipicephalus sanguineus is abundant in the
Mediterranean basin. When introduced to colder areas,
due to movements of the host (i.e., dogs travelling to and
returning from the Mediterranean region), it can survive
in kennels and other protected areas provided by
man-made constructions (Figure 1). The latitude at
which the tick can be established is currently unknown
[72,73]. Protected environments, such as a house, a
kennel, or the den of a wild carnivore, provide an ideal
environment for the reproduction and survival of tick
populations. It has been reported that even a single tick
female was sufficient to engorge and oviposit on a dog
inside an apartment, which then could give rise to theFigure 1 Distribution of Ixodes ricinus and Rhipicephalus sanguineus in
by the European Center for Disease Control (ECDC) in January, 2014 (red ar
can be ascribed to one of the NUTS (statistical regions of Europe). Many re
a country. Some of the areas in the Mediterranean region might be based
(i.e., casual introduction without further survival) or based on small areas of suit
belong to the R. sanguineus complex. Due to the confusion surrounding the m
be confidently tracked as “true” R. sanguineus. This northern limit is also an edu
may live in northern latitudes, protected in shelters, burrows, or private gardendevelopment of subadults [74]. Rhipicephalus sanguineus
populations can reach very high numbers in sheltered en-
vironments, because the blood supply necessary for their
development is guaranteed by the presence of hosts in
close proximity. In dogs without appropriate protection,
parasitic loads can reach hundreds of ticks per animal,
with ticks in all developmental stages.
The tick requires a minimum temperature of about 6°C
for adequate survival, and when temperatures drop
below this value, it may hibernate during winter, shel-
tered in the cracks of kennels and buildings. Ticks also
require a certain level of humidity, which is provided
by the high environmental moisture in the kennels
(cleaned with water) or in gardens that receive artificial
watering. Ticks are common and can reach significant
population densities on riverbanks of the Mediterranean
region, which are temperate and hold moisture. The tick
is mainly active from spring to early autumn, when the
highest infestations occur. The regional weather or the
local conditions of some buildings may result in a differ-
ent phenology or in different seasonal dynamics for the
tick [72]. The impact of climate trends on the tick is
unknown, although preliminary results have shown thatEurope. The reported distribution of I. ricinus was officially recorded
eas). The map includes only records with reliable, accurate data that
ports in the literature only mention the presence of one species in
on identified collections that do not have permanent populations
ability. The line shows the northern range of the distribution of ticks that
orphology and systematics of this complex group, many records cannot
cated guess for the current distribution, because persistent populations
s, where adequate conditions for survival may exist.
Sainz et al. Parasites & Vectors  (2015) 8:75 Page 5 of 20their area of distribution is increasing, due to the in-
crease in urbanized areas surrounding cities, and due to
the warmer environment observed in autumn and win-
ter at progressively higher latitudes.
Anaplasma phagocytophilum
Ixodes ricinus is the only known vector for A. phagocytophi-
lum in Europe. This tick is widely distributed in most
European regions, including western Norway and in Sweden;
it has been collected in mixed forests, open pastures, and
other areas with high humidity (Figure 1). The driving fea-
ture of the northern distribution is the temperature required
for tick development. In the northern areas of Sweden, the
tick was found at an approximate latitude of 68°N, but some
tick populations have spread even farther north [75]. Ixodes
ricinus is present in Ireland, the United Kingdom, and in
southern Finland. It is also present in almost every territory
in central Europe, and the eastern limit seems to be along
the Baltic countries and Ukraine. At its present limit to the
east, it coexists with the closely-related, species Ixodes persul-
catus, with which there is a certain degree of sympatry. In
the south, the tick is present in parts of the Mediterranean
region, commonly in mixed or deciduous forests [76,77]. It
has been detected in Portugal, Spain (only in northern areas
of the country and isolated points in southern hills),
and Italy. It is also common in the northern belt of
humid forests in Turkey [76,77]. It is hypothesized that
the driving feature of its southern distribution is the
atmospheric water vapour, which must be relatively
high (around 80%) to support permanent populations.
In the eastern regions of Europe, I. ricinus is replaced
with I. persulcatus, a closely related species. The habitats
of I. persulcatus extend to the east and into Japan [78].
This well-known parasite inhabits a wide range of domes-
tic animals, and it acts as a vector for different pathogens.
It is probably best known as the main vector for Borrelia
spp. and for tick-borne encephalitis virus in the territories
it colonizes [79]. I. persulcatus was found to be infected by
Ehrlichia spp. in the Baltic region [80] and by A. phagocy-
tophilum in Ukraine [81]. Members of the Anaplasmata-
ceae family (without further description) have also been
found in I. persulcatus collected in Moldova [82].
Anaplasma platys
The probable vector of A. platys in Europe is R. sangui-
neus. Experimental transmission has not been achieved
[83]. Nevertheless, molecular studies have detected A.
platys DNA in R. sanguineus ticks, which suggested that
these ticks act as the vector for A. platys [84].
Are there other routes of transmission for these
infections in dogs?
Outside the European continent (on which this guideline
is focused), other species of ticks have been shown to beresponsible for the transmission of E. canis [85]. How-
ever, to date, R. sanguineus appears to be the main
vector for this pathogen.
In general, another route of transmission is through
blood transfusion. Due to the potential transmission of
these pathogens via infected blood, screening canine
blood products for bacterial DNA with a polymerase chain
reaction (PCR) assay is recommended in highly endemic
areas to ensure the safety of blood products [86]. This
route of transmission has been described for E. canis [69],
A. phagocytophilum [87-89], and A. platys [90].
Are Ehrlichia and Anaplasma species present in dogs in
Europe able to affect other hosts?
Ehrlichia canis
Other wild canids (foxes, wolves, jackals) can become
infected with E. canis [91-93]. However, experimental
infection has only been reproduced in dogs. In addition,
E. canis-like DNA was claimed to be detected in cat
samples with PCR [94]. Moreover, several studies
reported the presence of E. canis DNA in cats and wild
felids from Brazil and Portugal [95-97]. However, to the
best of our knowledge, E. canis has not been isolated
from cats or other felids to date.
Anaplasma phagocytophilum
Anaplasma phagocytophilum can infect humans and
several animals other than dogs, including cats, sheep,
goats, cows, equines, rodents, roe deer, deer, other wild
mammals, and birds [98-100].
Anaplasma platys
Anaplasma platys DNA was also recently found in cats
in non-European continents [101,102].
What is the public health importance of E. canis,
A. phagocytophilum, and A. platys?
Ehrlichia canis
An organism closely related to E. canis has been de-
scribed in humans in Venezuela [103]. To date, it is not
considered an agent with important zoonotic potential.
Anaplasma phagocytophilum
Anaplasma phagocytophilum has important zoonotic
potential, because humans can acquire the infection
through a bite from a tick infected with the pathogen.
Anaplasma phagocytophilum causes human granu-
locytic anaplasmosis, a febrile illness that closely re-
sembles the disease in dogs. After infection (1-2
weeks), a syndrome frequently occurs of malaise, low-
back pain, fever, and/or gastrointestinal disorders.
Other, less frequent symptoms include arthralgia, lym-
phadenomegaly, conjunctivitis, dysuria, and peripheral
edema [104,105].
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was described by Bakken et al in 1994 in the USA [106].
After that description, numerous human cases from differ-
ent European countries were described [107]. Dogs may
act as sentinels for human exposure, because infected ticks
on their coats may travel to humans. Blood from infected
dogs should be handled with caution [107,108].
Anaplasma platys
Anaplasma platys DNA was recently detected in two
family members in the USA [109] and two women from
Venezuela [110].
Other Ehrlichia/Anaplasma spp. that have not been
described in Europe can also infect humans. Ehrlichia
ewingii has been described as a cause of infection in
immune-suppressed patients [111], but there is no evi-
dence of direct or tick-mediated transmission from dogs
to human beings. Ehrlichia ruminantium, which typic-
ally infects wild ruminants, is also able to cause a disease
in dogs [112] and humans [112,113]. Ehrlichia chaffeen-
sis is the etiologic agent of human monocytic ehrlichio-
sis [99]. Amblyomma americanum acts as a vector for
E. chaffeensis in the USA. Its hosts include white-tailed
deer, goats, domestic dogs, red foxes, and birds. This
Ehrlichia sp. has also been described in dogs [114,115],
and DNA of E. chaffeensis has been found in ticks col-
lected from dogs [116]. Finally, it has been shown that E.
muris can infect both humans and dogs [117,118].
Is there a breed, age, or sex predisposition for canine
ehrlichiosis or anaplasmosis?
Ehrlichia canis
All breeds are prone to CME. However, German Shepherd
dogs and Siberian Huskies are predisposed to develop
more severe clinical signs of ehrlichiosis; therefore, these
breeds have a worse prognosis [119,120]. This fact was
corroborated in experimental studies, which showed
that the cell-mediated immune response to a challenge
with E. canis was reduced in German Shepherd dogs
compared to Beagle dogs [119].
Canine ehrlichiosis may appear at any age. No sex pre-
disposition has been detected in the development of
CME. Some studies have found higher seropositivity in
males, but this may be explained by a higher exposure to
vectors than females, due to behavioral characteristics
[121]. Similarly, in epidemiological studies, higher sero-
positivity rates were found in older dogs [121-123]; this
observation may be attributed to a higher probability of
exposure to E. canis as the dog ages, rather than an in-
crease in susceptibility with age.
Anaplasma phagocytophilum
No breed predisposition has been confirmed for A. phago-
cytophilum infections. In a few studies, Retriever breedswere overrepresented; however, this might reflect the
popularity of taking these dogs along for outdoor activities
[124]. No sex or age predisposition has been documented
for clinical cases. Older dogs were more often seropositive
compared to younger dogs, probably due to an increased
opportunity for exposure over time [46,55].
Anaplasma platys
No breed, age, or sex predisposition has been described
for A. platys infections.
What stages of disease can be identified during infections
with Ehrlichia and/or Anaplasma spp. in dogs?
Ehrlichia canis
Following an incubation period of 1 to 3 weeks, three
typical phases of the disease may develop sequentially:
acute, subclinical, and chronic [2,125]. The acute phase
can last 2 to 4 weeks; then, clinical signs may vary or
disappear spontaneously, even without treatment. How-
ever, some dogs that show clinical improvement may
remain persistent subclinical carriers for months and
years [126]. The subclinical phase follows the acute
stage. Dogs in this stage present no clinical signs; there-
fore, they may not seem to require veterinary attention.
However, when screened for hematological abnormal-
ities, these dogs may have subnormal platelet concentra-
tions [127]. Some, but not all infected dogs may advance
to a chronic phase. In the chronic phase, the clinical
signs are more severe. Unfortunately, the acute and
chronic phases are not always easy to distinguish in
clinical practice, because many of the clinical signs are
similar. A complete blood count and bone marrow aspira-
tion may assist in diagnosing the chronic severe form
of the disease. Dogs in the chronic phase exhibit bone
marrow hypoplasia and severe pancytopenia [128]. No
studies have fully elucidated the different responses of
dogs to infection or the factors that induce some dogs to
develop the chronic severe form of the disease.
Anaplasma phagocytophilum
The incubation period for an A. phagocytophilum infec-
tion lasts 1 to 2 weeks. Thereafter, the dog may develop
a self-limiting febrile illness [87]. The main difference
between A. phagocytophilum and E. canis is that most
A. phagocytophilum cases present in the acute stage of
the disease. Indeed, most dogs naturally infected with A.
phagocytophilum probably remain healthy, as indicated
by the high number of healthy seropositive dogs relative
to dogs with the clinical disease [46]. The extent to
which A. phagocytophilum can persist in tissues and
contribute to subclinical/chronic disease manifestations
in dogs has been a controversial issue [129].
Three dogs experimentally inoculated with A. phagocy-
tophilum were monitored for 4 to 6 months to determine
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detected intermittently in two dogs, when PCR was per-
formed on blood samples throughout the study [129].
Anaplasma platys
The incubation period for an A. platys infection is similar
to that of an A. phagocytophilum infection (1 to 2 weeks).
After that, alternate periods of thrombocytopenia and
fever are observed, which appear and disappear cyclically
every 1-2 weeks [130].
After an experimental inoculation of dogs with A.
platys, parasitized platelets were detected in the periph-
eral blood after 8 to 15 days. The dogs developed severe
thrombocytopenia within 7 days post inoculation [90].
After a reduction in the number of circulating bacteria,
the platelet concentration increased within 3-4 days.
These episodes of bacteremia and thrombocytopenia oc-
curred at 1-2 week intervals. Chronic infection is associated
with low-level bacteremia and mild thrombocytopenia,
which may reflect a process where the host attempts to
adapt to the A. platys infection [131].
What clinical signs are associated to Ehrlichia spp. and
Anaplasma spp. infections in dogs?
Ehrlichia canis
Clinical signs of an E. canis infection can be variable,
depending on the strain, the immune response of the
dog, and the presence of concomitant infections with
other tick- or flea-borne pathogens. It must be kept in
mind that some dogs may not show clinical or labora-
tory signs associated with an Ehrlichia infection, and
others may show severe signs. In general, E. canis seems
to cause more severe clinical signs than anaplasmosis
[3,35,87,120,124,132-142].
Clinical signs of ehrlichiosis can vary, and it may in-
clude nonspecific signs, like fever, weakness, lethargy,
anorexia, lymphadenomegaly, splenomegaly, hepatomeg-
aly, or weight loss. Other signs have also been described,
including vomiting, diarrhea, pain, exercise intolerance,
edema (in hind legs, tail, or scrotum), cough and/or dys-
pnea (associated with pneumonia), serous or mucopuru-
lent oculonasal discharge, abortion or neonatal death,
and skin ulcers. Although some older studies have in-
cluded lameness, due to polyarthritis, as a sign of CME
[143,144], no evidence-based studies have supported this
sign. Therefore, in cases of lameness and/or polyarthritis
in dogs infected with E. canis, it is advisable to rule out
coinfections with other pathogens, such as A. phagocyto-
philum or B. burgdorferi.
Common clinical signs of ehrlichiosis include pale
mucous membranes, due to anemia, epistaxis, petechiae,
ecchymoses, prolonged bleeding during estrus, hematuria
or melena associated with thrombocytopenia, thrombocy-
topathy, or vasculitis. Ocular signs are also common inCME. The most common are anterior uveitis, corneal
opacity, hyphema, retinal vessel tortuosity, chorioretinal
lesions, subretinal hemorrhage, retinal detachment, or
blindness. Neurological signs are less commonly de-
scribed (typically secondary to meningitis).
Anaplasma phagocytophilum
The most common clinical signs of A. phagocytophilum
are non-specific; they include lethargy, inappetence/a-
norexia, and fever. Other findings are pale mucous
membranes, a tense abdomen, and gastrointestinal signs
(vomiting/diarrhea). Lameness may result from second-
ary immune-mediated (neutrophilic) polyarthritis. Mildly
enlarged lymph nodes, tachypnea, and surface bleeding
(petechiae, melena, epistaxis) may occur. Rare signs in-
clude collapse, mild cough, scleral injection, uveitis,
limb edema, and polydipsia/polyuria [145-151]. It is
controversial whether central nervous system signs are
associated with this infection [152-154]. In a few cases,
an association was suggested between steroid-responsive
meningitis/arteritis and A. phagocytophilum infection [155].
A. phagocytophilum infection may trigger some immunopa-
thies, such as immune-mediated thrombocytopenia/
anemia. Splenomegaly diagnosed with radiography and
ultrasonography is a very common finding [147].
Anaplasma platys
Clinical signs of A. platys infection have been described
both experimentally and in naturally infected dogs in
Greece, Spain, Portugal, and Israel. These signs included
fever, lethargy, anorexia, weight loss, pale mucous mem-
branes, petechiae, nasal discharge, and lymphadenome-
galy. Furthermore, single case studies have described
bilateral uveitis and epistaxis. However, not all studies
used PCR to exclude co-infections with other vector-
transmitted diseases that produce the same clinical signs
[54,62,63,66,146,156-158].
What abnormal laboratory findings can be found in dogs
with ehrlichiosis and/or anaplasmosis?
Abnormal laboratory findings in canine ehrlichiosis or
anaplasmosis are variable and nonspecific. However, the
most common finding in ehrlichiosis and anaplasmosis
is thrombocytopenia; this finding should alert clinicians.
Other common abnormal laboratory findings are shown
in Table 4 [54,147,148,159].
Is microscopic evaluation of a blood smear or another
tissue sample useful for the diagnosis of ehrlichiosis and
anaplasmosis?
The diagnostic usefulness of evaluating a blood smear
depends on the pathogen species that has infected
the dog.
Table 4 Laboratory abnormal findings in ehrlichiosis caused by Ehrlichia canis and anaplasmosis caused by Anaplasma
platys and Anaplasma phagocytophilum
Clinical disease Species Laboratory abnormal findings
Canine monocytyc ehrlichiosis E. canis • Mild to moderate normocytic normochromic
non regenerative anemia
• Neutropenia
• Neutrophilia
• Lymphopenia
• Monocytosis
• Granular lymphocytosis (uncommon)
• Thrombocytopenia
• Thrombocytopathy
• Pancytopenia: medullary hypoplasia or aplasia
(chronic forms, 15-20% of clinical cases)
• Hyperproteinemia
• Hyperglobulinemia
• Hypergammaglobulinemia, usually polyclonal
• Hypoalbuminemia
• Proteinuria
• Renal azotemia
• Mild increase in hepatic enzymes (ALT, ALP)
• Mononuclear or neutrophilic pleocytosis
Canine granulocytic anaplasmosis A. phagocytophilum • Non regenerative mild to moderate normocytic
normochromic anemia
• Regenerative anemia (rare)
• Lymphopenia
• Neutropenia, neutrophilia (sometimes left shift) or
normal neutrophil concentration
• Thrombocytopenia
• Hyperglobulinemia
• Hypoalbuminemia
• Increased ALP
• Mild hyperbilirubinemia
• Neutrophilic inflammation in synovial fluid
• Sometimes direct Coombs’ test/platelet-bound
antibody test positive
Canine thrombocytotrophic anaplasmosis A. platys • Thrombocytopenia
• Non regenerative mild to moderate normocytic
normochromic anemia
• Hyperglobulinemia
• Hypoalbuminemia
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It is rare to detect an E. canis morula (an aggregate of
E. canis organisms; Figure 2) in a blood smear. It occurs
in about 4-6% of clinical cases [160]. The highest like-
lihood of detecting morulae can be achieved by per-
forming a buffy coat smear [160]. Because the direct
detection method has low sensitivity, further diagnostic
tests must be conducted, such as serology or moleculartechniques (PCR). The highest rates of detecting morulae
(50%) seem to be achieved when lymph node aspirates are
examined by expert cytologists that evaluate a large
number of oil immersion fields [160,161].
Anaplasma phagocytophilum
The direct blood smear detection method seems to have
higher sensitivity for detecting A. phagocytophilum than
Figure 2 Microscopic image of a morula of Ehrlichia canis in the
cytoplasm of a monocyte (x100).
Figure 4 Microscopic image of a morula of Anaplasma platys in
a platelet (x100).
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neutrophils in up to 60% of clinical cases [147] (Figure 3).
In experimentally infected dogs, morulae appear as
early as 4 days after inoculation and persist for 4-8 days
[129]. However, the morulae cannot be distinguished
from those of other Ehrlichia spp. that infect neutro-
phils (e.g., Ehrlichia ewingii); therefore, the finding
should be confirmed by PCR in areas where both organ-
isms are likely to occur.
Anaplasma platys
The method of detecting morulae in platelets during an
A. platys infection also appears to have a low sensitivity
(Figure 4) [57], but some studies suggest that this
method may have higher sensitivity during the early phase
of the infection [162]. It was recently reported that A.Figure 3 Microscopic image of a morula of Anaplasma
phagocytophilum in the cytoplasm of a neutrophil (x100).platys were found in megakaryocytes [163], but the sensi-
tivity of bone marrow cytology remains to be evaluated.
What serological techniques can be used in the diagnosis
of ehrlichiosis and/or anaplasmosis?
Ehrlichiosis and/or anaplasmosis can be diagnosed with
the IFAT or ELISA [142,164,165]. These tests require
specific equipment and trained technicians. One of the
advantages of these tests is that they allow determination
of antibody levels and their changes over time. There-
fore, it is important to conduct quantitative serologic
tests and to determine either the final antibody titer with
the IFAT or the optical density with the ELISA for a
quantitative evaluation (negative, low, or high signals).
Quantitative laboratory techniques are more sensitive
and specific than rapid tests [164]. Some commercial in-
house dot-ELISA kits are qualitative, and show only a
positive or negative result, without providing the dog’s
antibodies levels. Other dot-ELISA kits are semi-
quantitative and provide some information on anti-
body levels. However, an accurate, reliable serological
diagnosis is limited by the lack of standardization
among different diagnostic laboratories and tests.
How should we interpret a positive serologic result for
Ehrlichia and/or Anaplasma?
A positive serologic result indicates a past or current in-
fection, but it does not always denote an ongoing disease
condition. A single positive titer result may only reflect a
past infection that may be resolved, because antibody
titers may persist for several months or years [46,90,126].
Moreover, seroprevalence is high in endemic areas. In
dogs naturally infected with E. canis, some authors have
found that animals with high IFAT titers were more likely
to show PCR positivity than negativity; this finding
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body titer and active infection [166]. Nevertheless, this in-
formation must be confirmed. We suggest that suspected
cases should be evaluated based on the performance of
two or more serological tests conducted in 2-4 weeks
intervals. This approach can provide information on anti-
body kinetics (an increase, no change, or a decrease),
which may point to the current status of infection. It has
been suggested that a four-fold increase in IgG antibodies
over time can be taken as evidence of an ongoing infection
[165]. Recent research has suggested that the combination
of serology and PCR was preferable for the diagnosis of
Ehrlichia and Anaplasma spp. infections [167]. Presently,
we recommend performing molecular tests to support any
positive serological case, because the presence of bacterial
DNA is a sign of active infection.
Could a seronegative dog be infected with Ehrlichia and/
or Anaplasma spp.?
A dog can be seronegative, despite harboring an infec-
tion, with some species of Ehrlichia or Anaplasma. This
is particularly common during the incubation period
and in the early stages of the acute disease, when bacterial
loads are low, for example:
– In the case of E. canis, antibody production typically
does not occur before 12 -14 days post-infection
[126,168].
– After experimentally infecting dogs with A.
phagocytophilum, IgG antibodies may first be
detectable 8 days after the initial exposure and 2 to
5 days after the appearance of morulae [129].
– After experimentally infecting dogs with A. platys,
antibodies were first detected on day 16 [90].
Consequently, seroconversion can be used as a sero-
logic technique to corroborate signs that suggest an
acute infection with Ehrlichia or Anaplasma. Thus, an
initial quantitative serology is conducted to detect acute
antibody levels, when the dog shows clinical signs and/
or abnormal laboratory findings; then, another quantita-
tive serology is conducted to detect convalescent anti-
body levels after 2-4 weeks. Positive antibody levels in
the convalescent stage confirm the infection for some
species of Ehrlichia and/or Anaplasma at disease onset.
It should be noted that the administration of doxycycline
will take effect over days and weeks; therefore, it will
have no impact on the production of antibodies or the
seroconversion [90,168-171].
Do serological cross reactions exist among E. canis,
A. phagocytophilum, and A. platys?
It is generally accepted that no important cross reac-
tion exists between Ehrlichia and Anaplasma. However, apotential cross reaction has been described between
E. canis and A. phagocytophilum, particularly when one
of the pathogens is present at very high titers or when
the follow up is prolonged [37,165]. Apparently, there
is no serological cross reaction between E. canis and
A. platys; however, only a few, limited serologic studies
have investigated this possibility [172].
When antibodies cross-react with more than one anti-
gen/pathogen, the antibody titers that are highest indi-
cate the most probable infecting pathogen in the dog
[37]. However, a cross reaction was described between
A. phagocytophilum and A. platys [37,173]. Moreover,
A. phagocytophilum might cross react with other non-
ehrlichial species (e.g., Coxiella burnettii) [54,145].
As serological cross reactions may occur between dif-
ferent Ehrlichia and Anaplasma species, the serology
should be complemented with molecular techniques,
such as PCR and DNA sequencing.
Why is a polymerase chain reaction assay useful in the
diagnosis of these diseases?
PCR is very useful in diagnosing these infectious dis-
eases for several reasons. First, PCR detection is more
sensitive than a direct microscopic examination. Second,
the detection of DNA for a specific pathogen in a clinical
setting should be considered evidence of an active
infection. Third, real-time PCR permits quantification
of bacterial loads. Finally, PCR allows one to investigate
specific gene fragments after amplification. Sequencing
the gene fragment/s amplified by PCR may reveal the
identification of the specific Ehrlichia/Anaplasma spe-
cies that infected the dog.
Real-time PCR assays that were developed for detect-
ing infections of Ehrlichia or Anaplasma in peripheral
blood have provided high sensitivity, similar to the sensi-
tivity previously obtained with splenic samples [169,174].
Several third-party laboratories provide various PCR
assays for detecting Ehrlichia and/or Anaplasma spp.
However, the results depend on the experience and qual-
ity of the laboratory. The use of non-specific primers
and low annealing temperatures in some PCR assays can
result in non-specific amplification; thus, the evaluation
may provide misleading, false-positive results.
Finally, it must be kept in mind that false-negative
results can also occur due to the absence of pathogens
in the sample. For example, bacteremia may be intermit-
tent in some dogs or in specific diseases (e.g., A. platys
infection); it may be present below the minimal detec-
tion level of the assay [174,175]; or it may be absent,
due to previous administration of antibiotics, such as
doxycycline. Therefore, a negative PCR result should be
interpreted as “no detection of the tested pathogen-
DNA in the sample”, rather than “the sample is free of
the tested pathogen”. Thus, to improve the usefulness
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from the results, it is important to submit samples to
reliable laboratories and to assess the results in combina-
tion with an evaluation of antibody titers, clinical signs,
and abnormal laboratory findings.
What samples should be chosen to perform a molecular
diagnosis of Ehrlichia and/or Anaplasma spp. infections?
The sample of choice for a PCR assay is peripheral
blood, buffered with EDTA. Some studies have suggested
that splenic aspirates seem to be optimal specimens for
the diagnosis of E. canis infections based on PCR [176].
When microscopic examination reveals structures sug-
gestive of morulae in the cytoplasm of neutrophils or
mononuclear cells in any tissue or fluid, PCR can be
used to corroborate the diagnosis.
Are coinfections common in dogs infected with Ehrlichia
and/or Anaplasma spp.?
Coinfections with Ehrlichia and/or Anaplasma spp. are
common, because some species are transmitted in the
same arthropod vector [145,177]. Accordingly, coinfec-
tion of E. canis with A. platys should occur frequently.
Currently, many other vector-borne diseases have been
shown to coexist in the same dog, including other tick-
borne pathogens (Babesia and Hepatozoon spp.), Culicidae
mosquito-borne pathogens (Dirofilaria and other filariae),
sand fly-borne pathogens (Leishmania infantum) [33,162],
and even intestinal parasites [178]. In the Mediterranean
basin, the most common coinfecting agents are L. infan-
tum and Babesia spp. Less common are coinfections
with Hepatozoon spp.
Due to the shared arthropod vectors and/or concurrent
exposure to multiple vector-carrying ticks, co-infections
may occur with other tick-borne pathogens (e.g., Borrelia,
Bartonella, Rickettsia, Babesia, and arboviral spp.), which
can complicate the clinical picture [179]. Because Borrelia
burgdorferi and A. phagocytophilum are transmitted by
the same ixodid tick species, coinfections with these two
pathogens are frequently detected. Moreover, the two
organisms may enhance one another’s pathogenicity
[180]. In northern California, dogs that are seroreactive
to A. phagocytophilum were 18 times more likely to be
seropositive for Bartonella vinsonii subs. berkhoffii than
dogs seronegative for A. phagocytophilum [181].
What is the clinical significance of a coinfection during
the course of the disease?
Coinfections tend to worsen some conditions and mask
others, which could complicate the diagnosis [131].
Most vector-borne diseases have the special feature of
causing similar clinical signs and abnormal laboratory
findings in dogs (e.g., epistaxis and uveitis are signs that
can be due to ehrlichiosis and/or leishmaniosis). Thissimilarity complicates the diagnosis and increases the
list of differential diagnoses. In one study, a coinfection
with CME and Leishmania sp. delayed clinical improve-
ment compared to dogs with either CME or leishmanio-
sis alone [182]. In another study, more clinical signs
were noticed in dogs with dual infections (E. canis and
L. infantum), which supported the notion that the path-
ogens may have synergistic pathological effects [183].
Furthermore, the occurrence of A. platys together with
other infectious agents (e.g., E. canis, Babesia vogeli, or
Rickettsia conorii) may potentiate the clinical disease
and the laboratory abnormalities [54,66,90].
Therefore, when an infection of one specific species is
diagnosed, a comprehensive work-up is necessary to rule
out coinfections with other vector-borne pathogens [177].
What is the treatment of choice for Ehrlichia spp. and
Anaplasma spp. infections?
Ehrlichia canis
CME is usually successfully treated with antibiotics that
belong to the tetracycline family. The treatment of
choice is doxycycline at 5 mg/kg twice daily or 10 mg/kg
once daily for 4 weeks. This regime guarantees a complete
response in the majority of cases [125,168,176]. Some
reports described experimentally infected dogs that
remained infected and became subclinical carriers after
shorter treatments with doxycycline, even at the recom-
mended doses [125,166,170]. Therefore, the more pro-
longed treatment of 4 weeks is recommended.
Although clinical improvement is achieved in most
cases, it can be difficult to ensure treatment effectiveness
regarding the total elimination of Ehrlichia spp. in nat-
urally infected dogs. The clinician should not target
seronegativity with treatment, but rather, negative PCR
results [6,142,166,168].
Doxycycline, unlike other tetracyclines, does not seem
to cause enamel discoloration in puppies. Moreover, one
of the most common side effects of tetracyclines, vomit-
ing, can be eliminated by splitting the antibiotic dose
into two half-doses every 12 h (q12h) or by administer-
ing the antibiotic after feeding. When the dog has liver
problems, the use of doxycycline should be reconsidered.
In any case, liver function tests should be performed be-
fore and during treatment; when liver parameters increase,
the treatment regime should be stopped [6,142,166,168].
Other drugs have been historically used for treating
CME. Chloramphenicol has been used in dogs under 1
year of age, but its use is not recommended when doxy-
cycline is available. Imidocarb dipropionate has also
been described as a potential treatment for ehrlichiosis
in dogs [171,184,185]. Recent studies performed in vitro
and in experimentally infected dogs showed that imido-
carb dipropionate was not effective against E. canis
[186,187]. It should only be used in cases of co-infection
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otics, such as rifampicin or levofloxacin, have been ef-
fective in in vitro studies [188]. However, recent studies
have shown that, in experimental infections, rifampicin
contributed to improving laboratory findings, but it was
not effective in eliminating the infection [189].
A. phagocytophilum
Doxycycline (for 2-3 weeks) at the dosage described
above for E. canis is apparently effective in treating A.
phagocytophilum infections. However, several parame-
ters remain to be established, including the most effec-
tive or optimal dose; the length of doxycycline
treatment; and the value of adding other antibiotics
[145,146,174,175,190]. Rifampin and levofloxacin have
also shown in vitro effects against A. phagocytophilum
[190]. Chloramphenicol has been mentioned as an alterna-
tive for treating puppies [191].
When dogs with circulating Anaplasma organisms
have moderate to severe clinical disease or do not
rapidly respond to doxycycline therapy, they should
probably be tested for other tick-borne diseases [146].
Anaplasma platys
Anaplasma platys infections can be treated with tetracy-
clines (e.g., doxycycline 5-10 mg/kg q12-24h for 8-10
days). Alternatively, they can be treated with enrofloxa-
cin at 5 mg/kg, q12h for 14-21 days [131,192].
Are there other supportive therapies that could be used
for ehrlichiosis and/or anaplasmosis?
In severe or chronic ehrlichiosis and/or anaplasmosis,
other therapeutic agents or treatments may be needed, par-
ticularly for E. canis infections. For cases with hemorrhage
or organic lesions, the dog may require admission to a hos-
pital for a more intensive treatment. In general, according
to the seriousness determined in the clinic, dogs may need
blood transfusions when the packed cell volume (PCV)
is very low; fluid therapy when dehydration or second-
ary kidney disease is present; or antipyretic and anal-
gesic drugs [138,142,146].
In some cases of chronic ehrlichiosis, when aplasia of
all cell lines occurs, other treatments have been used.
For example, growth factors, like granulocyte colony
stimulating factor or erythropoietin have been used;
however, scientific evidence of effectiveness is scarce.
One case of chronic ehrlichiosis was treated successfully
with a combination of hematopoietic growth factors, low
dose vincristine, doxycycline, and glucocorticoids [193].
Is it necessary to use steroids for treating ehrlichiosis
and/or anaplasmosis?
Treatment of ehrlichiosis or anaplasmosis should not be
initiated with glucocorticoids combined with antibiotics.Steroids should only be considered when no satisfactory
response is noticed, or when immune-mediated compli-
cations arise. Ehrlichia and Anaplasma species may medi-
ate an immune response, typically indicated by hemolytic
anemia, thrombocytopenia, uveitis, glomerulonephritis,
vasculitis, etc. In those cases, treatment with glucocorti-
coids (usually prednisone or prednisolone) may be indi-
cated; doses of prednisone should range from 0.5 to 2 mg/
kg/day, and the treatment duration should vary according
to the type and seriousness of the associated immune-
mediated condition [133,147,152,194-196]. However, the
use of immunosuppressive glucocorticoids for treatment
of secondary immune-mediated diseases must be con-
sidered very carefully. Of note, the administration of
immunosuppressive doses of glucocorticoids or other
drugs to subclinically infected dogs may result in the re-
emergence of bacteremia, although the dog may not
show clinical signs [6,129,142,174,175].
What is the expected clinical response following the
treatment of ehrlichiosis and/or anaplasmosis?
Doxycycline is an effective drug against ehrlichiosis and/
or anaplasmosis in dogs [120,145,146]. When dogs are
treated in the acute phase of ehrlichiosis and anaplasmo-
sis, they improve quickly, within 24-48 h, and their prog-
nosis is good when the whole course of therapy is
administered [120,147,197].
However, the prognosis of dogs with the chronic se-
vere form of ehrlichiosis is grave [120,197]. Shipov and
colleagues (2008) investigated prognostic indicators for
mortality and survival in canine ehrlichiosis [198]. They
found that pronounced pancytopenia (white blood cells
[WBC] < 4 × 103/μL; PCV < 25%; and platelet concen-
tration [PLT] < 50 × 103/μL) was a risk factor for mor-
tality. In that study, they found that severe leucopenia
(WBC < 0.93 × 103/μL), severe anemia (PCV < 11.5%),
prolonged activated partial thromboplastin time (APTT
> 18.25 s), and hypokalemia (K < 3.65 mmol/L) could
each predict mortality with a probability of 100%. Con-
versely, a WBC > 5.18 × 103/μL, PLT > 89.5 × 103/μL,
PCV > 33.5%, APTT < 14.5 s, or K > 4.75 mmol/L could
each predict survival with a probability of 100%.
When the clinical response in canine ehrlichiosis or
anaplasmosis is not rapid, or when clinical signs persist
after treatment with doxycycline, the dog must be re-
examined for other infectious diseases or diseases with
similar clinical signs (neoplasia or immune-mediated
diseases) [6,142,146].
How do abnormal laboratory findings evolve in dogs
infected with ehrlichiosis/anaplasmosis after the treatment?
Ehrlichia canis
Laboratory abnormalities in canine ehrlichiosis typically
resolve in dogs after treatment with acute disease. In
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in serum protein electrophoresis should normalize within
10-15 days after therapy initiation [6,142].
Chronic changes, such as mild or moderate hyperglo-
bulinemia, anemia, or thrombocytopenia may persist as
long as the infectious agent has not been completely
eliminated, or when some other associated conditions
exist [171]. In naturally infected dogs, despite evident
clinical improvement, it is difficult to guarantee treat-
ment effectiveness and complete elimination of the
involved pathogens [6,142]. When the dog no longer
produces specific antibodies to the pathogen, it can be
assumed that complete elimination of the Ehrlichia spe-
cies has been achieved [120].
Quantification of acute phase proteins in serum has
been assessed for its value in monitoring and evaluating
the prognosis of dogs with ehrlichiosis. Although quanti-
fication of acute phase proteins may be a useful indica-
tor of the clinical stage, it has no predictive value for the
final clinical outcome [199].
Finally, it must be recognized that prior infections with E.
canis do not confer permanent immunity to dogs. There-
fore, dogs can be re-infected with the same pathogen or
with other species after re-exposure to infected ticks [6,142].
Anaplasma phagocytophilum
Similar to canine ehrlichiosis, after treating anaplasmo-
sis, laboratory alterations in the complete blood cell
count and in serum protein electrophoresis should be
resolved in most dogs [146,147].
Anaplasma platys
Thrombocytopenia in dogs infected with A. platys typically
disappears around one week after starting therapy [192].
How do antibody titers evolve following treatment?
Ehrlichia canis
Antibody titers may persist for months. Then, in most
E. canis infections, they decrease gradually over 6-9
months post treatment. Sometimes, antibodies are no
longer detectable at 12 months. However, frequently, some
cases remain seropositive for several years after the
treatment [194], particularly when starting with very
high antibody titers [171].
Anaplasma phagocytophilum
Information regarding the persistence of A. phagocyto-
philum antibody titers is limited. However, some studies
have described persistence of seropositivity for up to one
year after the treatment [200].
Anaplasma platys
Information regarding antibody titers in dogs naturally
infected with A. platys is scarce. A steady decline ofantibody titers after therapy has been described in dogs
experimentally infected with A. platys [90].
Why is PCR useful after treatment?
PCR testing, when conducted several weeks after
termination of doxycycline treatment, allows clinicians
to be more confident that the treatment has been
effective and that the dog did not enter the subclinical
stage [6,142,146,186,201]. Yet, it must be recognized
that a negative PCR result does not guarantee that the
animal is “free of infection” (see above).
There are two goals for performing PCR some weeks
after the completion of treatment. One is to minimize
the probability of obtaining false-negative results, due
to antibiotic effects on bacteremia. The second is to
minimize the chance of detecting DNA of dead patho-
gens that continue to circulate during the treatment
period [6,132,142,174,175].
In conclusion, PCR is useful for monitoring dogs
treated for these diseases, because it can detect the pres-
ence of pathogen DNA, regardless of the serologic anti-
body titers. However, although this technique is more
sensitive than serology in confirming an infection, its
effectiveness may be limited for detecting pathogens in
subclinically infected dogs, because the organisms may
circulate intermittently in peripheral blood. Therefore, a
PCR analysis should not be considered a definitive
method for conclusively excluding subclinical infection
in clinically normal dogs that remain seropositive after
treatment [6,142,145,146].
Can canine ehrlichiosis and/or anaplasmosis be cured?
In general, most acutely ill dogs infected with Ehrlichia
or Anaplasma species heal after a specific, effective
treatment of appropriate length. This finding has been
corroborated with multiple clinical and experimental
trials [166,168,170]. However, a recent work conducted
with dogs experimentally infected with E. canis sug-
gested that some dogs may remain persistently infected
and may not eliminate the infection even after accept-
able treatment [125].
Can dogs be re-infected by Ehrlichia and/or Anaplasma
spp.?
Ehrlichia canis
Re-infections of canine ehrlichiosis are possible, because
no persistent or effective immunity develops to defend
against re-infection with these pathogens [120]. In most
cases, after treatment, the dogs return to the habitat they
lived in prior to the infection; therefore, their exposure
to infected ticks remains feasible. When no proper tick-
control measures are employed, and the dogs are re-
exposed, they can easily become re-infected. Moreover,
mainly in cases of canine ehrlichiosis, it is difficult to
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lished persistent subclinical condition [177].
Anaplasma phagocytophilum
It is not known whether a natural infection can provide
long term protection against the development of clinical
anaplasmosis. Re-infection following the therapeutic
elimination of the organism has not been reported in
dogs; however, in human medicine, one re-infection case
was documented [202]. Conversely, horses have been
shown to resist re-infection after recovery from an initial
infection with A. phagocytophilum [200].
Anaplasma platys
The possibility of A. platys re-infections in dogs living in
endemic areas and exposed to ticks has not been fully
evaluated, but cannot be ruled out.
What prophylactic measures can be implemented to prevent
infection by Ehrlichia and/or Anaplasma spp. in dogs?
The prevention of ehrlichiosis and/or anaplasmosis in-
fections in dogs must be focused on tick control. Ticks
of the R. sanguineus complex are mainly found indoors,
but other populations of the tick may be common in
gardens, pastures, and fields in the Mediterranean basin.
Therefore, dogs may become infected with the most
common tick present in infested private gardens or ken-
nels, but also, whenever they are engaged in an activity that
involves contact with natural green areas. Nevertheless, to
prevent transmission, actions must focus mainly on:
– preventing dogs from becoming infested in the field,
which is the source of peridomestic parasitism. This
infestation can introduce ticks to indoor habitats
(kennels, etc.), which will result in a large
population, due to their high reproductive capacity.
– preventing dogs from becoming infested with ticks,
even when they live in a peridomestic environment
with abundant ticks. This objective is more difficult
to achieve than the former, due to the high
parasitism pressure that can arise from those
populations of ticks [203].
To appropriately control tick infestations in dogs
requires knowledge of tick seasonality. This seasonality
is usually strict under natural conditions, and each stage
of the life cycle of the tick follows the previous stage
with regularity. However, these patterns can be lost in
areas with large infestations in a peridomestic environ-
ment. Under those conditions, all stages can be active
simultaneously, due to the presence of several infesta-
tions in the kennel.
Outdoor populations of R. sanguineus can be active
and, therefore infest dogs, when the average temperatureis 10-12°C. Below this temperature, it is very rare that
dogs acquire infestations from outdoor populations of
that tick; consequently, during winter, it may be appro-
priate to reduce the treatment pressure against ticks.
However, it must be noted that indoor populations of
the ticks may be active year round, which adds extra risk
for dogs living in kennels or dogs that spend time in dog
day care centers. In Europe, tick control should be con-
tinuous between spring and autumn in areas where ticks
are present. This pattern may vary according to the local
weather and the historic weather particularities. Clearly,
measures against R. sanguineus must follow extended
schedules in the Mediterranean basin, because winters
are shorter, and therefore, the periods of R. sanguineus
activity are prolonged.
In the case of I. ricinus, the activation temperature for
the ticks may be around 6°C. Therefore, adequate mea-
sures of control should be strictly followed to limit con-
tact of dogs with ticks in infested areas [72].
Various antiparasitic treatments are registered in
Europe that have activity against ticks and can be pre-
scribed for dogs [204]. The specific product can be
selected according to the preferences of use (collar,
pour-on, or spot on) and the therapeutic needs for each
case. Some compounds, such as the pyrethroids or some
preparations of diazinon, are registered as repellents.
Apart from appropriate epidemiological measures, the
best prevention against dog tick infestation is based on
the use of ectoparasiticides. In general, these are active
molecules that act against ticks, and they must also pro-
vide some degree of appropriate control within a short
period of time [205]. Rapid action could contribute to
the elimination of attached ticks before they are able
to transmit pathogens. To optimize efficacy, preventive
chemicals must be applied at the recommended time in-
tervals, based on the length of efficacy claimed by the
manufacturer. Although knowledge may be lacking for
some diseases, most tick-borne pathogens require 4 to
48 h to complete their development in the salivary gland
and enter the bloodstream [100]. However, a recent
report showed that transmission of E. canis can occur
within shorter periods of time (e.g., 3 h) [71].
Are there vaccines available to prevent ehrlichiosis and/or
anaplasmosis in dogs?
Currently, no commercial vaccines are available to pro-
tect against infections with E. canis, A. phagocytophilum,
or A. platys. A recent study showed that an attenuated
E. canis strain may serve as an effective future vaccine
for CME [206].
Conclusions
Information on canine ehrlichiosis and anaplasmosis in
Europe has significantly increased in the last few years.
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interest on the etiology, transmission, epidemiology,
clinical signs, laboratory findings, diagnosis, therapy,
and prophylaxis of infections caused by Ehrlichia and
Anaplasma spp. This guideline contributes to the
understanding of the current status of these diseases on
the European continent. However, these pathogens are
spreading to new niches, and reports have described
infections in many countries where they were not
detected previously.
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and the multiple studies recently conducted on these diseases in that
country. Subsequently, the group decided that this guideline could have
greater relevance by broadening the scope to the European continent.
Consequently, we invited other European scientists working on these
diseases to participate in this project. This guideline was the result of a
complete review of the literature. The experience of all the authors has been
included, and a consensus among them was reached.
The questions included in this document are intended to address the most
common concerns about these diseases, and we provided answers from a
practical point of view.
The authors Member of ENTRA group are Ángel Sainz, Xavier Roura,
Guadalupe Miró, Agustín Estrada-Peña and Laia Solano-Gallego.
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